K
Kerstin Schmidt
Researcher at Howard Hughes Medical Institute
Publications - 9
Citations - 7324
Kerstin Schmidt is an academic researcher from Howard Hughes Medical Institute. The author has contributed to research in topics: KRAS & Mutation. The author has an hindex of 8, co-authored 9 publications receiving 6465 citations. Previous affiliations of Kerstin Schmidt include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
PatentDOI
Circulating Mutant DNA to Assess Tumor Dynamics
TL;DR: In this article, a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients was applied to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy.
Journal ArticleDOI
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.
Jihye Yun,Carlo Rago,Ian Cheong,Ray Pagliarini,Ray Pagliarini,Philipp Angenendt,Harith Rajagopalan,Harith Rajagopalan,Kerstin Schmidt,James K V Willson,Sandy D. Markowitz,Shibin Zhou,Luis A. Diaz,Victor E. Velculescu,Christoph Lengauer,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos +18 more
TL;DR: Studying the transcriptomes of paired colorectal cancer cell lines that differed only in the mutational status of their KRAS or BRAF genes, it is suggested that glucose deprivation can drive the acquisition of KRAS pathway mutations in human tumors.
Journal ArticleDOI
Development of personalized tumor biomarkers using massively parallel sequencing.
Rebecca J. Leary,Isaac Kinde,Frank Diehl,Kerstin Schmidt,Christopher Clouser,Cisilya Duncan,Alena A. Antipova,Clarence Lee,Kevin McKernan,Francisco M. De La Vega,Kenneth W. Kinzler,Bert Vogelstein,Luis A. Diaz,Victor E. Velculescu +13 more
TL;DR: In an arena that takes small steps, PARE offers a leap forward in the clinical management and treatment of solid tumors, revealing true biomarkers that enable monitoring of individual tumor progression, tailoring of response to therapeutic treatment, and identification of residual disease at a level previously undetectable by current methods.
Journal ArticleDOI
Sensitive digital quantification of DNA methylation in clinical samples
Meng Li,Wei Dong Chen,Nickolas Papadopoulos,Steven N. Goodman,Niels Christian Bjerregaard,Søren Laurberg,Bernard Levin,Hartmut Juhl,Nadir Arber,Helen Moinova,Kris Durkee,Kerstin Schmidt,Yiping He,Frank Diehl,Victor E. Velculescu,Shibin Zhou,Luis A. Diaz,Kenneth W. Kinzler,Sanford D. Markowitz,Bert Vogelstein +19 more
TL;DR: Methyl-BEAMing technology is developed to enable absolute quantification of the number of methylated molecules in a sample and should be applicable to preclinical assessment of new epigenetic biomarkers and quantitative analyses in epigenetic research.